Sood AK - Search Results

1

Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma.

Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. Matsuo K, et al. Among authors: sood ak. Gynecol Oncol. 2010 Jan;116(1):61-5. doi: 10.1016/j.ygyno.2009.09.018. Epub 2009 Oct 17. Gynecol Oncol. 2010. PMID: 19840886 Free PMC article.

2

Taxol hypersensitivity: rapid retreatment is safe and cost effective.

Olson JK, Sood AK, Sorosky JI, Anderson B, Buller RE. Olson JK, et al. Among authors: sood ak. Gynecol Oncol. 1998 Jan;68(1):25-8. doi: 10.1006/gyno.1997.4906. Gynecol Oncol. 1998. PMID: 9454655

3

Hematogenous skin metastases from cervical cancer at primary presentation.

Pertzborn S, Buekers TE, Sood AK. Pertzborn S, et al. Among authors: sood ak. Gynecol Oncol. 2000 Mar;76(3):416-7. doi: 10.1006/gyno.1999.5704. Gynecol Oncol. 2000. PMID: 10684721

4

Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy.

Sood AK, Shahin MS, Sorosky JI. Sood AK, et al. Gynecol Oncol. 2001 Dec;83(3):599-600. doi: 10.1006/gyno.2001.6439. Gynecol Oncol. 2001. PMID: 11733979

5

Ovarian cancer p53 mutation is associated with tumor microvessel density.

Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE. Goodheart MJ, et al. Among authors: sood ak. Gynecol Oncol. 2002 Jul;86(1):85-90. doi: 10.1006/gyno.2002.6730. Gynecol Oncol. 2002. PMID: 12079305

6

Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia.

Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JI. Lowe MP, et al. Among authors: sood ak. Gynecol Oncol. 2003 Dec;91(3):569-72. doi: 10.1016/j.ygyno.2003.08.007. Gynecol Oncol. 2003. PMID: 14675678

7

Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.

Hsu Y, Sood AK, Sorosky JI. Hsu Y, et al. Among authors: sood ak. Am J Clin Oncol. 2004 Feb;27(1):14-8. doi: 10.1097/01.coc.0000045849.95834.6b. Am J Clin Oncol. 2004. PMID: 14758127

8

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sood AK, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5. doi: 10.1158/1078-0432.CCR-04-0574. Clin Cancer Res. 2004. PMID: 15447993 Clinical Trial.

9

Malignant mixed mullerian tumor (MMMT) of the cervix.

Sharma NK, Sorosky JI, Bender D, Fletcher MS, Sood AK. Sharma NK, et al. Among authors: sood ak. Gynecol Oncol. 2005 May;97(2):442-5. doi: 10.1016/j.ygyno.2005.01.022. Gynecol Oncol. 2005. PMID: 15863143 Review.

10

Fifth International Conference on Ovarian Cancer: challenges and opportunities.

Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Sood AK, et al. Gynecol Oncol. 2005 Jun;97(3):916-23. doi: 10.1016/j.ygyno.2005.03.013. Gynecol Oncol. 2005. PMID: 15907981

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,140 results

Search Page